Pfizer is hoping to challenge other biologics in the competitive AD market, which is currently dominated by blockbuster sellers, Dupixent and Rinvoq.
Pfizer is ramping up plans for tilrekimig after a phase 2 win raised hopes that the once-monthly trispecific antibody could hold its own against approved eczema drugs. | Pfizer is ramping up plans for ...
Investor sentiment toward Pfizer remains cautious despite a significant development in its dermatology pipeline. The pharmaceutical giant announced accelerated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results